Investor Relations

Print   Email  
Stock price graph

Ocera is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's lead program, OCR-002, is an ammonia scavenger designed to treat hyperammonemia (elevated ammonia in the blood) and associated hepatic encephalopathy, a complication of patients with liver cirrhosis. In addition to OCR-002, Ocera has developed Zysa™ (AST-120), a spherical carbon adsorbent, for the treatment of irritable bowel syndrome.

View all »   RSSRecent Releases

Jul 31, 2014
Ocera Therapeutics to Announce Second Quarter Financial Results

Jul 10, 2014
Ocera Therapeutics Raises $25.2 Million in Public Offering

View all »Events & Presentations

Sep 8, 2014
Rodman & Renshaw 16th Annual Global Investment Conference